Brown Advisory Inc. grew its position in Coherus Biosciences Inc (NASDAQ:CHRS) by 4.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 659,266 shares of the biotechnology company’s stock after buying an additional 25,222 shares during the period. Brown Advisory Inc. owned 0.97% of Coherus Biosciences worth $10,879,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. BlueMountain Capital Management LLC purchased a new stake in shares of Coherus Biosciences in the 2nd quarter valued at approximately $214,000. Royal Bank of Canada boosted its position in shares of Coherus Biosciences by 26.2% during the 1st quarter. Royal Bank of Canada now owns 32,526 shares of the biotechnology company’s stock worth $360,000 after purchasing an additional 6,754 shares during the period. Tower Research Capital LLC TRC purchased a new position in shares of Coherus Biosciences during the 2nd quarter worth approximately $118,000. Swiss National Bank boosted its position in shares of Coherus Biosciences by 7.6% during the 2nd quarter. Swiss National Bank now owns 70,500 shares of the biotechnology company’s stock worth $987,000 after purchasing an additional 5,000 shares during the period. Finally, Point72 Asset Management L.P. purchased a new position in shares of Coherus Biosciences during the 2nd quarter worth approximately $4,379,000. 93.31% of the stock is owned by institutional investors and hedge funds.
A number of equities analysts recently weighed in on CHRS shares. Zacks Investment Research cut shares of Coherus Biosciences from a “hold” rating to a “sell” rating in a research report on Monday, August 13th. BidaskClub raised shares of Coherus Biosciences from a “hold” rating to a “buy” rating in a research report on Friday, August 24th. HC Wainwright started coverage on shares of Coherus Biosciences in a research report on Tuesday, August 28th. They set a “buy” rating and a $28.00 price objective for the company. ValuEngine cut shares of Coherus Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 14th. Finally, Maxim Group reaffirmed a “buy” rating and set a $25.00 price objective on shares of Coherus Biosciences in a research report on Tuesday, September 25th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. Coherus Biosciences currently has an average rating of “Hold” and a consensus price target of $27.20.
In related news, insider Barbara K. Finck sold 1,760 shares of the stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $18.58, for a total transaction of $32,700.80. Following the completion of the transaction, the insider now owns 38,803 shares of the company’s stock, valued at approximately $720,959.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 19.57% of the company’s stock.
NASDAQ:CHRS opened at $11.06 on Monday. The company has a quick ratio of 5.31, a current ratio of 5.31 and a debt-to-equity ratio of 8.29. Coherus Biosciences Inc has a fifty-two week low of $8.20 and a fifty-two week high of $20.66.
Coherus Biosciences (NASDAQ:CHRS) last posted its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.87) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.79) by ($0.08). On average, sell-side analysts expect that Coherus Biosciences Inc will post -3.12 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Brown Advisory Inc. Has $10.88 Million Stake in Coherus Biosciences Inc (CHRS)” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/12/03/brown-advisory-inc-has-10-88-million-stake-in-coherus-biosciences-inc-chrs.html.
About Coherus Biosciences
Coherus BioSciences, Inc, a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis.
Read More: When is a capital gain realized?
Want to see what other hedge funds are holding CHRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Coherus Biosciences Inc (NASDAQ:CHRS).
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.